0001140361-21-025680.txt : 20210727 0001140361-21-025680.hdr.sgml : 20210727 20210727070055 ACCESSION NUMBER: 0001140361-21-025680 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210726 ITEM INFORMATION: Other Events FILED AS OF DATE: 20210727 DATE AS OF CHANGE: 20210727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 211115886 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 brhc10027259_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2021

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number) 
(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock
 ADMA
 Nasdaq Global Market
Preferred Share Purchase Rights
-
 Nasdaq Global Market

Item 8.01
Other Events

ADMA Biologics, Inc. (the “Company”) was a party to the Open Market Sale AgreementSM, dated August 5, 2020, with Jefferies LLC (“Jefferies”), which was previously amended by Amendment No. 1 to the Open Market Sale AgreementSM, dated November 5, 2020, by and between the Company and Jefferies, and Amendment No. 2 to the Open Market Sale AgreementSM, dated February 3, 2021, by and between the Company and Jefferies (as so amended, the “Sale Agreement”). Pursuant to the Sale Agreement, the Company could offer to sell, from time to time through Jefferies, shares of the Company’s common stock (the “Shares”) having an aggregate offering price of up to approximately $105.4 million.

On July 27, 2021, the Company announced that as of July 26, 2021 it had sold the maximum amount of the Shares permitted to be sold under the Sale Agreement, and in accordance with the terms of the Sale Agreement, the Sale Agreement terminated automatically upon the sale of all such Shares. In aggregate, the Company generated approximately $105.4 million in gross proceeds from the sale of the Shares under the Sale Agreement.

2
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

July 27, 2021
ADMA Biologics, Inc.
 
 
 
By: 
/s/ Brian Lenz
 
 
Name: 
Brian Lenz
 
 
Title:
Executive Vice President and Chief Financial Officer


3
 EX-101.SCH 2 adma-20210726.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 adma-20210726_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 adma-20210726_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Preferred Share Purchase Rights [Member] EX-101.PRE 5 adma-20210726_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 brhc10027259_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2021-07-26 2021-07-26 0001368514 adma:PreferredSharePurchaseRightsMember 2021-07-26 2021-07-26 0001368514 us-gaap:CommonStockMember 2021-07-26 2021-07-26 false 0001368514 0 8-K 2021-07-26 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false false Common Stock ADMA NASDAQ Preferred Share Purchase Rights NASDAQ XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 26, 2021
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 26, 2021
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36728
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001368514
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Preferred Share Purchase Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Preferred Share Purchase Rights
Trading Symbol 0
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10027259_8k.htm adma-20210726.xsd adma-20210726_def.xml adma-20210726_lab.xml adma-20210726_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10027259_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "adma-20210726_def.xml" ] }, "inline": { "local": [ "brhc10027259_8k.htm" ] }, "labelLink": { "local": [ "adma-20210726_lab.xml" ] }, "presentationLink": { "local": [ "adma-20210726_pre.xml" ] }, "schema": { "local": [ "adma-20210726.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 1, "memberStandard": 1, "nsprefix": "adma", "nsuri": "http://admabiologics.com/20210726", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10027259_8k.htm", "contextRef": "c20210726to20210726", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10027259_8k.htm", "contextRef": "c20210726to20210726", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "adma_PreferredSharePurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Share Purchase Rights [Member]" } } }, "localname": "PreferredSharePurchaseRightsMember", "nsuri": "http://admabiologics.com/20210726", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-21-025680-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-025680-xbrl.zip M4$L#!!0 ( !LX^U+0S$*NT0, #L1 1 861M82TR,#(Q,#K,J"_(5E.92I$$RB0,"@LF,BSP-:AU2 MS3@/WES__MO5'V%X!P(4-9"1^9K7SZ@$,@KR>Q_PH'5ATN"_FA9\P2$+"/H@]&RE.UW/S\^3YXN)5#DJ MB9/H\_N'CX[=RUJRHY@;D ?>&74;/I1?'TS+J"35065,^=L-]Q?H9Q$EXD'J25 M^1ZJV]H#RXP:P+9

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end